An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency

Trial Profile

An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions
  • Acronyms VISTA
  • Sponsors Versartis
  • Most Recent Events

    • 27 Jul 2017 According to a Versartis media release, data will be presented at the 10th Annual International Joint Meeting of Pediatric Endocrinology (IMPE) Sep 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2017 Planned number of patients changed from 300 to 400.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top